AGI-6780 is a potent and selective IDH2 inhibitor. AGI-6780 inhibits the tumor-associated mutant IDH2/R140Q. Treatment with AGI-6780 induced differentiation of TF-1 erythroleukemia and primary human acute myelogenous leukemia cells in vitro. Inhibitors targeting mutant IDH2/R140Q could have potential applications as a differentiation therapy for cancer.
Dehydrogenase Inhibitors Related Products:
Mycophenolate mofetil; AGI-5198; SW033291; Vidofludimus; Devimistat (CPI-613); Mycophenolic acid; Trilostane; Tenovin-1; Teriflunomide; Gimeracil; AG-636; AG-120 (racemic); Ivosidenib; Brequinar